Literature DB >> 9391890

Misleading linkage results in an NF2 presymptomatic test owing to mosaicism.

E K Bijlsma1, A J Wallace, D G Evans.   

Abstract

A two generation family with neurofibromatosis type 2 (NF2) is presented in which a family member requested presymptomatic molecular diagnosis. Since the consultand's mother had clinically well defined NF2, he was quoted to be at 50% risk of carrying an NF2 mutation. Mutation screening in the mother did not show the causative mutation and, consequently, presymptomatic testing was based on linkage analysis. This showed that the consultand carried the high risk chromosome 22. Subsequent mutation screening of his clinically affected sister showed a nonsense mutation, R262X in exon 8 of the NF2 gene. The mother turned out to be a mosaic for R262X; the son had not inherited the mutation. Mosaicism may be a common mechanism in NF2 and other autosomal dominant diseases with a high new mutation rate. This may be one explanation for a difference in expression in generations. Caution has to be exercised when giving results based on linkage tests which imply a very high risk to people in the second generation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9391890      PMCID: PMC1051124          DOI: 10.1136/jmg.34.11.934

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  15 in total

1.  Highly polymorphic dinucleotide repeat at the NF2 gene.

Authors:  D Bourn; T Strachan
Journal:  Hum Genet       Date:  1995-06       Impact factor: 4.132

2.  A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor.

Authors:  J A Trofatter; M M MacCollin; J L Rutter; J R Murrell; M P Duyao; D M Parry; R Eldridge; N Kley; A G Menon; K Pulaski
Journal:  Cell       Date:  1993-03-12       Impact factor: 41.582

3.  A mutation in the neurofibromatosis type 2 tumor-suppressor gene, giving rise to widely different clinical phenotypes in two unrelated individuals.

Authors:  D Bourn; S A Carter; D G Evans; J Goodship; H Coakham; T Strachan
Journal:  Am J Hum Genet       Date:  1994-07       Impact factor: 11.025

4.  Presymptomatic diagnosis for neurofibromatosis 2 with chromosome 22 markers.

Authors:  M H Ruttledge; S A Narod; J P Dumanski; D M Parry; R Eldridge; W Wertelecki; J Parboosingh; M C Faucher; G M Lenoir; V P Collins
Journal:  Neurology       Date:  1993-09       Impact factor: 9.910

5.  A clinical study of type 2 neurofibromatosis.

Authors:  D G Evans; S M Huson; D Donnai; W Neary; V Blair; V Newton; R Harris
Journal:  Q J Med       Date:  1992-08

6.  Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2.

Authors:  G A Rouleau; P Merel; M Lutchman; M Sanson; J Zucman; C Marineau; K Hoang-Xuan; S Demczuk; C Desmaze; B Plougastel
Journal:  Nature       Date:  1993-06-10       Impact factor: 49.962

7.  Diagnostic issues in a family with late onset type 2 neurofibromatosis.

Authors:  D G Evans; D Bourn; A Wallace; R T Ramsden; J D Mitchell; T Strachan
Journal:  J Med Genet       Date:  1995-06       Impact factor: 6.318

8.  Screening for germ-line mutations in the NF2 gene.

Authors:  P Mérel; K Hoang-Xuan; M Sanson; E Bijlsma; G Rouleau; P Laurent-Puig; S Pulst; M Baser; G Lenoir; J M Sterkers
Journal:  Genes Chromosomes Cancer       Date:  1995-02       Impact factor: 5.006

9.  Central neurofibromatosis with bilateral acoustic neuroma: genetic, clinical and biochemical distinctions from peripheral neurofibromatosis.

Authors:  W R Kanter; R Eldridge; R Fabricant; J C Allen; T Koerber
Journal:  Neurology       Date:  1980-08       Impact factor: 9.910

10.  Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity.

Authors:  D M Parry; R Eldridge; M I Kaiser-Kupfer; E A Bouzas; A Pikus; N Patronas
Journal:  Am J Med Genet       Date:  1994-10-01
View more
  7 in total

Review 1.  Neurofibromatosis type 2.

Authors:  D G Evans; M Sainio; M E Baser
Journal:  J Med Genet       Date:  2000-12       Impact factor: 6.318

2.  Probability of bilateral disease in people presenting with a unilateral vestibular schwannoma.

Authors:  D G Evans; R Lye; W Neary; G Black; T Strachan; A Wallace; R T Ramsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-06       Impact factor: 10.154

3.  Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification.

Authors:  D Gareth R Evans; R T Ramsden; A Shenton; C Gokhale; N L Bowers; S M Huson; G Pichert; A Wallace
Journal:  J Med Genet       Date:  2007-02-16       Impact factor: 6.318

4.  Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations.

Authors:  D G Evans; L Trueman; A Wallace; S Collins; T Strachan
Journal:  J Med Genet       Date:  1998-06       Impact factor: 6.318

5.  Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas.

Authors:  L Kluwe; V Mautner; B Heinrich; R Dezube; L B Jacoby; R E Friedrich; M MacCollin
Journal:  J Med Genet       Date:  2003-02       Impact factor: 6.318

Review 6.  Genetic mosaics and the germ line lineage.

Authors:  Mark E Samuels; Jan M Friedman
Journal:  Genes (Basel)       Date:  2015-04-17       Impact factor: 4.096

7.  Genetic Severity Score predicts clinical phenotype in NF2.

Authors:  Dorothy Halliday; Beatrice Emmanouil; Pieter Pretorius; Samuel MacKeith; Sally Painter; Helen Tomkins; D Gareth Evans; Allyson Parry
Journal:  J Med Genet       Date:  2017-08-28       Impact factor: 6.318

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.